1887

n Health SA Gesondheid - Prescribing patterns of antiretroviral drugs in a section of the private health care sector of South Africa : research

USD

 

Abstract

The general objective of this study was to investigate the prescribing patterns and cost of antiretroviral (ARV) drugs in the private health care sector in South Africa by using a medicine claims database. A quantitative, retrospective drug utilisation review was performed on data retrieved from 2001, 2002 and 2004 records. Antiretroviral drugs represented 0.38% (n = 1 475 380) for 2001, 0.72% (n = 2 076 236) for 2002, and 1.68% (n = 2 595 254) for 2004 of all studied prescriptions. The total cost of the ARV drugs represented 1.31% (R379 708 489) for 2001, 3.03% (R601 350 325) for 2002, and increased to 5.25% (R661 223 146) for 2004 of all drugs claimed. All ARV medicine items claimed during 2001 (n = 9 796) and 2002 (n = 35 271) were innovator products. Only 5.23% (n=5 329) of all the ARV medicine items (n = 101 938) claimed during 2004 were generic products. The average cost per ARV medicine item for 2004 increased from R317.93 (SD = R190.80) for the period January to April to R369.20 (SD = R219.50) for the period May to August, and decreased to R324.79 (SD = R212.48) for the period September to December and resulted in a cost saving of R41 044.35 for the period May to August versus September to December. Both the prevalence and cost of ARV drug therapy increased from 2001 to 2002. The prevalence increased from 2002 to 2004, but the cost decreased during 2004. The decrease in the cost of ARV drug therapy is probably a result of the implementation of the new pricing regulations in May 2004.

Die doel van hierdie studie was om die voorskryfpatrone en medisynekoste van antiretrovirale (ARV) geneesmiddels in die private gesondheidsorgsektor in Suid-Afrika te ondersoek. 'n Kwantitatiewe, retrospektiewe studie van medisyneverbruik vir die jare 2001, 2002 en 2004 is met behulp van 'n medisyne-eise databasis uitgevoer. Antiretrovirale geneesmiddels verteenwoordig vir 2001 0.38% (n = 1 475 380), vir 2002 0.72% (n = 2 076 236) en vir 2004 1.68% (n = 2 595 254) van alle bestudeerde voorskrifte. ARV geneesmiddels verteenwoordig 1.31% (R379 708 489) van die totale koste van medisyne geëis vir 2001, 3.03% (R601 350 325) vir 2002 en toon 'n styging tot 5.25% (R661 223 146) vir 2004. Alle ARV geneesmiddels wat gedurende 2001 (n = 9 796) en 2002 (n = 35 271) geëis is, was oorspronklike produkte. Slegs 5.23% (n = 5 329) van die ARV geneesmiddels (n = 101 938) wat gedurende 2004 geëis is, was generiese produkte. Die gemiddelde koste vir ARV medisyne-items het in 2004 soos volg toegeneem: R317.93 (SA = R190.80) vir Januarie tot April, neem toe na R369.20 (SA = R219.50) vir Mei tot Augustus. 'n Afname is gevind in die September- tot Desember-periode, naamlik R324.79 (SA = R212.48) wat 'n kostebesparing van R41 044.35 veroorsaak het vir die tydperk Mei tot Augustus versus September tot Desember. Beide die voorkoms en koste van antiretrovirale geneesmiddelterapie het toegeneem van 2001 tot 2002. Die voorkoms het van 2002 tot 2004 toegeneem, maar die koste van geneesmiddelterapie het gedurende 2004 afgeneem. Die afname in koste kan moontlik die gevolg wees van die instelling van nuwe prysregulasies in Mei 2004.

Loading

Article metrics loading...

/content/health/11/4/EJC35003
2006-12-01
2016-12-06
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error